Benign
Prostatic Hyperplasia (BPH) Procedures are expected to grow at
a CAGR of 2.3% during 2017 – 2023, according to P&S Market Research.
Increasing life expectancy and fall in the birth rates
are the major reasons for rise in the aging population. The people in this
category require extensive care, since they are more prone to illness due to
low immunity levels and longer recovery time. Increase in the aging population
in the U.S., Germany, China and India in the next few years, is expected to
create high demand for BPH treatment devices, since the population aged 50
years and above is more prone to BPH, and therefore tend to opt for various
treatments that involve the use of procedures such as TURP, prostate implants
and laser based treatments. Thus, growing aging population acts as a strong
driver supporting the increase in the number of BPH procedures performed.
According to the National Institute of Health, it has
been estimated that around 14 million men in the U.S. had symptoms suggestive
of BPH, which can affect 50% of men aged between 51 and 60 years of age, and up
to 90% of men aged more than 80 years. With 50% of men getting affected with
BPH, there is a consequent increase in the BPH procedures.
As per the findings of the research, surgical procedure
held the largest share in the global BPH procedures, primarily due to
increasing prevalence of BPH disorders. The number of laser based procedure is
expected to register fastest growth during the forecast period since these
procedures are as effective as surgical procedures and reduce the hospital stay
time. Hospitals held the largest share of the number of BPH procedures
performed, based on the end user. Ambulatory surgical centers are expected to
witness the highest inflow of BPH patients for treatment during the forecast
period, due to development of technologically advanced BPH procedures and
rising prevalence of BPH disorders leading to the growth in the number of patients
treated in the ambulatory surgical centers.
Download
Report Sample at:
Geographically, Europe accounted for the largest number
of BPH procedures done in 2016. Growing ageing population, lower cost of BPH
treatment as compared to the U.S., high healthcare spending, and technological
advancements in the field of urological procedures technology are some of the
factors driving the growth of the BPH procedures in the Europe. France, Germany
and the U.K. are expected to be the most promising countries for the growth in
number of the BPH procedures. In June 2016, National Institute of Health and
Care Excellence (NICE) approved GreenLight XPS laser treatment for the
treatment of BPH. NICE added that the widespread adoption of the procedure
could save the National Health Services (NHS) an estimated $4.3 million (£3
million) a year. Asia-Pacific is expected to witness the high number of BPH
procedures performed during the forecast period, owing to the rising prevalence
of BPH disorders, increasing disposable income, aging population, and growing
efforts to increase awareness about advanced BPH treatment procedures.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=benign-prostatic-hyperplasia-procedures
There has been an increase in the use of minimally
invasive procedures such as TUIP, laser based treatments, due to which several
technological advancements are being done in the field of urology. Various
treatment methods, such as the use of Rezum system and pulsed electromagnetic
field therapy (PEMF), are being developed for the treatment of BPH. Rezum
system manufactured by NxThera is a device that utilizes radiofrequency energy
to create thermal energy in the form of water vapor to destroy excessive
prostatic tissue growth caused by BPH, to resolve patient symptoms through a
minimally invasive procedure, with few or no side effects.
Key players are in the process of introducing new
advanced products for BPH treatment procedures. For instance, in May 2016, Olympus
Corporation (Olympus), announced the launch of USFDA cleared Plasma-OvalButton,
an addition to the company’s Plasma Loops and electrodes product portfolio that
utilizes Olympus’ plasma technology for urologic procedures, including
minimally invasive surgery to reduce benign prostate hyperplasia (BPH).
In March 2016, Lumenis
Ltd. (Lumenis), announced the expansion of its comprehensive Urology portfolio
with the launch of Lumenis Pulse 30H, at the European Association of Urology
Congress, in Munich.
Some of the other key players operating in the global BPH
procedures include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC.,
Karl Storz GmbH & Co. KG, Lumenis Ltd., Olympus Corporation, Advin Urology,
Convergent Laser Technologies, Richard Wolf GmbH, Medtronic Plc.
GLOBAL BPH PROCEDURES SEGMENTATION
By Type
·
Surgical
procedure
o Transurethral resection of
the prostate (TURP)
o Transurethral incision of the
prostate (TUIP)
·
Laser
based procedure
o Holmium lasers
o Green light lasers
o Thulium lasers
o Others
·
Other
energy based procedure
o Transurethral microwave
thermotherapy (TUMT)
o Transurethral needle ablation
(TUNA)
o High-intensity focused
ultrasound (HIFU) and water-induced thermotherapy
o Others
By End User
·
Hospitals
·
Specialty
clinics
·
Ambulatory
surgery centers
By Geography
·
North
America
o The U.S.
o Canada
·
Europe
o France
o Germany
o The U.K.
o Italy
o Spain
o Rest of Europe
·
Asia-Pacific
o Australia
o Japan
o South Korea
o Rest of Asia-Pacific
·
RoW
